Northern Capital Management LLC reduced its position in Monsanto Co. (NYSE:MON) by 2.5% during the second quarter, Holdings Channel reports. The fund owned 36,565 shares of the company’s stock after selling 945 shares during the period. Monsanto makes up about 1.7% of Northern Capital Management LLC’s portfolio, making the stock its 13th largest position. Northern Capital Management LLC’s holdings in Monsanto were worth $3,781,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently added to or reduced their stakes in the company. Howard Hughes Medical Institute purchased a new stake in Monsanto during the first quarter worth $110,000. Bartlett & Co. LLC increased its stake in Monsanto by 10.6% in the second quarter. Bartlett & Co. LLC now owns 1,402 shares of the company’s stock worth $145,000 after buying an additional 134 shares during the last quarter. Carnick & Kubik LLC purchased a new stake in Monsanto during the first quarter worth $130,000. Palladium Partners LLC purchased a new stake in Monsanto during the second quarter worth $205,000. Finally, First Quadrant L P CA increased its stake in Monsanto by 42.9% in the second quarter. First Quadrant L P CA now owns 2,000 shares of the company’s stock worth $207,000 after buying an additional 600 shares during the last quarter. Institutional investors own 79.06% of the company’s stock.
Shares of Monsanto Co. (NYSE:MON) traded up 0.40% on Friday, hitting $102.20. The stock had a trading volume of 3,664,239 shares. The company has a market cap of $44.72 billion, a P/E ratio of 44.98 and a beta of 1.24. Monsanto Co. has a 12 month low of $83.73 and a 12 month high of $114.26. The company’s 50 day moving average price is $105.24 and its 200-day moving average price is $100.93.
Monsanto (NYSE:MON) last issued its quarterly earnings results on Wednesday, June 29th. The company reported $2.17 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $2.40 by $0.23. Monsanto had a return on equity of 37.98% and a net margin of 7.76%. The business had revenue of $4.19 billion for the quarter, compared to the consensus estimate of $4.49 billion. During the same period in the prior year, the business posted $2.39 earnings per share. Monsanto’s revenue was down 8.5% on a year-over-year basis. On average, analysts expect that Monsanto Co. will post $4.46 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, October 28th. Investors of record on Friday, October 7th will be paid a dividend of $0.54 per share. This represents a $2.16 dividend on an annualized basis and a dividend yield of 2.11%. The ex-dividend date is Wednesday, October 5th. Monsanto’s dividend payout ratio is currently 89.26%.
A number of analysts recently weighed in on the company. S&P Equity Research restated a “positive” rating on shares of Monsanto in a research report on Thursday, September 15th. JPMorgan Chase & Co. reiterated a “hold” rating on shares of Monsanto in a research report on Thursday, June 30th. Zacks Investment Research downgraded Monsanto from a “hold” rating to a “sell” rating in a research report on Friday, July 1st. Vetr upgraded Monsanto from a “buy” rating to a “strong-buy” rating and set a $117.09 price objective for the company in a research report on Wednesday, August 3rd. Finally, Jefferies Group reiterated a “buy” rating on shares of Monsanto in a research report on Wednesday, June 29th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $114.31.
In other Monsanto news, COO Brett D. Begemann sold 27,980 shares of Monsanto stock in a transaction on Thursday, July 14th. The stock was sold at an average price of $103.62, for a total transaction of $2,899,287.60. Following the completion of the sale, the chief operating officer now directly owns 102,480 shares of the company’s stock, valued at approximately $10,618,977.60. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Michael K. Stern sold 12,797 shares of Monsanto stock in a transaction on Wednesday, July 13th. The shares were sold at an average price of $101.77, for a total value of $1,302,350.69. Following the sale, the chief executive officer now directly owns 21,583 shares of the company’s stock, valued at $2,196,501.91. The disclosure for this sale can be found here. Corporate insiders own 0.88% of the company’s stock.
Monsanto Company (Monsanto), along with its subsidiaries, is a provider of agricultural products for farmers. The Company provides seeds, biotechnology trait products, herbicides and precision agriculture tools to farmers. The Company operates through two segments: Seeds and Genomics, and Agricultural Productivity.
Want to see what other hedge funds are holding MON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Monsanto Co. (NYSE:MON).
Receive News & Ratings for Monsanto Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monsanto Co. and related companies with MarketBeat.com's FREE daily email newsletter.